{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:53:18Z","timestamp":1790142798527,"version":"4.0.1"},"reference-count":51,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AstraZeneca Farmac\u00e9utica Spain, S.A."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The SRealCLL study aimed to obtain real-world evidence on the clinical characteristics and treatment patterns of patients with chronic lymphocytic leukemia (CLL) using natural language processing (NLP). Electronic health records (EHRs) from seven Spanish hospitals (January 2016\u2013December 2018) were analyzed using EHRead\u00ae technology, based on NLP and machine learning. A total of 534 CLL patients were assessed. No treatment was detected in 270 (50.6%) patients (watch-and-wait, W&amp;W). First-line (1L) treatment was identified in 230 (43.1%) patients and relapsed\/refractory (2L) treatment was identified in 58 (10.9%). The median age ranged from 71 to 75 years, with a uniform male predominance (54.8\u201363.8%). The main comorbidities included hypertension (W&amp;W: 35.6%; 1L: 38.3%; 2L: 39.7%), diabetes mellitus (W&amp;W: 24.4%; 1L: 24.3%; 2L: 31%), cardiac arrhythmia (W&amp;W: 16.7%; 1L: 17.8%; 2L: 17.2%), heart failure (W&amp;W 16.3%, 1L 17.4%, 2L 17.2%), and dyslipidemia (W&amp;W: 13.7%; 1L: 18.7%; 2L: 19.0%). The most common antineoplastic treatment was ibrutinib in 1L (64.8%) and 2L (62.1%), followed by bendamustine + rituximab (12.6%), obinutuzumab + chlorambucil (5.2%), rituximab + chlorambucil (4.8%), and idelalisib + rituximab (3.9%) in 1L and venetoclax (15.5%), idelalisib + rituximab (6.9%), bendamustine + rituximab (3.5%), and venetoclax + rituximab (3.5%) in 2L. This study expands the information available on patients with CLL in Spain, describing the diversity in patient characteristics and therapeutic approaches in clinical practice.<\/jats:p>","DOI":"10.3390\/cancers15164047","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T10:24:47Z","timestamp":1691663087000},"page":"4047","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Real-World Evidence on the Clinical Characteristics and Management of Patients with Chronic Lymphocytic Leukemia in Spain Using Natural Language Processing: The SRealCLL Study"],"prefix":"10.3390","volume":"15","author":[{"given":"Javier","family":"Loscertales","sequence":"first","affiliation":[{"name":"Hematology Department, Hospital Universitario de la Princesa, Calle de Diego de Le\u00f3n 62, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Abrisqueta-Costa","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitari Vall d\u2019Hebron, Pg de la vall d\u2019Hebron 199, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9062-077X","authenticated-orcid":false,"given":"Antonio","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Son Espases\/IdISBa, Carretera de Valldemossa 79, 07120 Palma de Mallorca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4550-757X","authenticated-orcid":false,"given":"Jos\u00e9 \u00c1ngel","family":"Hern\u00e1ndez-Rivas","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario Infanta Leonor, Avda. Gran V\u00eda del Este 80, 28031 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Andreu-Lapiedra","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario La Fe, Avinguda de Fernando Abril Martorell 106, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Mora","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital de la Santa Creu i Sant Pau, Calle de St. Antoni Maria Claret 167, 08025 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Leiva-Farr\u00e9","sequence":"additional","affiliation":[{"name":"Medical Department, Astrazeneca Farmac\u00e9utica Spain S.A., Calle del Puerto de Somport 21, 28050 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"L\u00f3pez-Roda","sequence":"additional","affiliation":[{"name":"Medical Department, Astrazeneca Farmac\u00e9utica Spain S.A., Calle del Puerto de Somport 21, 28050 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Callejo-Mell\u00e9n","sequence":"additional","affiliation":[{"name":"Medical Department, Astrazeneca Farmac\u00e9utica Spain S.A., Calle del Puerto de Somport 21, 28050 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"\u00c1lvarez-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Medical Department, Astrazeneca Farmac\u00e9utica Spain S.A., Calle del Puerto de Somport 21, 28050 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Garc\u00eda-Marco","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Calle Joaqu\u00edn Rodrigo 1, 28222 Majadahonda, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","article-title":"Chronic lymphocytic leukaemia","volume":"3","author":"Kipps","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canep.2014.12.001","article-title":"Racial differences in three major NHL subtypes: Descriptive epidemiology","volume":"39","author":"Li","year":"2015","journal-title":"Cancer Epidemiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/ejh.12468","article-title":"Survival for patients with chronic leukemias in the US and Britain: Age-related disparities and changes in the early 21st century","volume":"94","author":"Pulte","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1001\/jama.2014.14553","article-title":"Chronic lymphocytic leukemia: A clinical review","volume":"312","author":"Nabhan","year":"2014","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Carretero, C., Gonz\u00e1lez-Gasc\u00f3n-Y-Mar\u00edn, I., Rodr\u00edguez-Vicente, A.E., Quijada-\u00c1lamo, M., Hern\u00e1ndez-Rivas, J.-\u00c1., Hern\u00e1ndez-S\u00e1nchez, M., and Hern\u00e1ndez-Rivas, J.M. (2021). The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment. Diagnostics, 11.","DOI":"10.3390\/diagnostics11050853"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Gasc\u00f3n-Y-Mar\u00edn, I., Mu\u00f1oz-Novas, C., Rodr\u00edguez-Vicente, A.-E., Quijada-\u00c1lamo, M., Hern\u00e1ndez-S\u00e1nchez, M., P\u00e9rez-Carretero, C., Ramos-Ascanio, V., and Hern\u00e1ndez-Rivas, J.-\u00c1. (2021). From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct. Cancers, 13.","DOI":"10.3390\/cancers13081782"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1016\/j.clml.2021.07.022","article-title":"Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)","volume":"21","author":"Abrisqueta","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_13","unstructured":"GELLC (2023, March 08). Gu\u00edas de Tratamiento de LLC. Available online: https:\/\/www.gellc.es\/images\/pdf\/guias_gellcv1.pdf."},{"key":"ref_14","unstructured":"(2023, March 08). Cancer Stat Facts: Leukemia\u2014Chronic Lymphocytic Leukemia (CLL). 2021, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bjh.18736","article-title":"Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed\/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)","volume":"202","author":"Spacek","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Laurenti, L., Scarfo, L., Frustaci, A.M., Sanna, A., Iannella, E., Caira, M., Finsinger, P., Schifano, S., Neri, B., and Molica, S. (2023). Real-world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience. Hematol. Oncol.","DOI":"10.1002\/hon.3122"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/10428194.2022.2148220","article-title":"Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program","volume":"64","author":"Mulligan","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clml.2023.03.010","article-title":"Treatment Discontinuation Patterns for Patients with Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study","volume":"23","author":"Shadman","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s44228-022-00020-8","article-title":"Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study","volume":"4","author":"Janssens","year":"2022","journal-title":"Clin. Hematol. Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1007\/s12325-021-01991-5","article-title":"Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status","volume":"39","author":"Huang","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s44228-022-00015-5","article-title":"FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL","volume":"4","author":"Dartigeas","year":"2022","journal-title":"Clin. Hematol. Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cam4.3855","article-title":"Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare population","volume":"10","author":"Goyal","year":"2021","journal-title":"Cancer Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.2217\/fon-2021-0964","article-title":"Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia","volume":"17","author":"Hou","year":"2021","journal-title":"Future Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/hon.2861","article-title":"Efficacy of idelalisib and rituximab in relapsed\/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group","volume":"39","author":"Rigolin","year":"2021","journal-title":"Hematol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"106335","DOI":"10.1016\/j.leukres.2020.106335","article-title":"Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada","volume":"91","author":"Huang","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s11899-020-00584-3","article-title":"Utilizing Real-World Evidence (RWE) to Improve Care in Chronic Lymphocytic Leukemia: Challenges and Opportunities","volume":"15","author":"Islam","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3324\/haematol.2018.200204","article-title":"First-line therapy in chronic lymphocytic leukemia: A Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013","volume":"104","author":"Sylvan","year":"2019","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1182\/blood-2019-126588","article-title":"Retrospective Non-Interventional Assessment of the Use of Idelalisib in Relapsed\/Refractory Chronic Lymphocytic Leukemia Patients in Spain","volume":"134","author":"Ferra","year":"2019","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Marchetti, M., Vitale, C., Rigolin, G.M., Vasile, A., Visentin, A., Scarfo, L., Coscia, M., and Cuneo, A. (2022). Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence. J. Clin. Med., 11.","DOI":"10.3390\/jcm11082076"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s40545-020-00276-6","article-title":"Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy","volume":"13","author":"Medrano","year":"2020","journal-title":"J. Pharm. Policy Pract."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3414\/ME14-02-0018","article-title":"Scaling-up NLP Pipelines to Process Large Corpora of Clinical Notes","volume":"54","author":"Divita","year":"2015","journal-title":"Methods Inf. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s40264-017-0558-6","article-title":"Natural Language Processing for EHR-Based Pharmacovigilance: A Structured Review","volume":"40","author":"Luo","year":"2017","journal-title":"Drug Saf."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e20773","DOI":"10.2196\/20773","article-title":"Natural Language Processing for Rapid Response to Emergent Diseases: Case Study of Calcium Channel Blockers and Hypertension in the COVID-19 Pandemic","volume":"22","author":"Neuraz","year":"2020","journal-title":"J. Med. Internet Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e12239","DOI":"10.2196\/12239","article-title":"Natural Language Processing of Clinical Notes on Chronic Diseases: Systematic Review","volume":"7","author":"Sheikhalishahi","year":"2019","journal-title":"JMIR Med. Inform."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2003142","DOI":"10.1183\/13993003.03142-2020","article-title":"The Impact of COVID-19 on Patients with Asthma","volume":"57","author":"Izquierdo","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1089\/jwh.2020.8721","article-title":"Evidence of gender differences in the diagnosis and management of COVID-19 patients: An analysis of Electronic Health Records using Natural Language Processing and machine learning","volume":"30","author":"Ancochea","year":"2021","journal-title":"J. Womens Health"},{"key":"ref_37","first-page":"23","article-title":"Savana: A Global Information Extraction and Terminology Expansion Framework in the Medical Domain","volume":"57","author":"Tello","year":"2016","journal-title":"Proces. Leng. Nat."},{"key":"ref_38","first-page":"8","article-title":"Savana: Re-using Electronic Health Records with Artificial Intelligence","volume":"4","author":"Guijarro","year":"2017","journal-title":"Int. J. Interact. Multimed. Artif. Intell."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Graziani, D., Soriano, J.B., Del Rio-Bermudez, C., Morena, D., D\u00edaz, T., Castillo, M., Alonso, M., Ancochea, J., Lumbreras, S., and Izquierdo, J.L. (2020). Characteristics and Prognosis of COVID-19 in Patients with COPD. J. Clin. Med., 9.","DOI":"10.20944\/preprints202009.0242.v1"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e21801","DOI":"10.2196\/21801","article-title":"Clinical Characteristics and Prognostic Factors for Intensive Care Unit Admission of Patients With COVID-19: Retrospective Study Using Machine Learning and Natural Language Processing","volume":"22","author":"Izquierdo","year":"2020","journal-title":"J. Med. Internet Res."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Bhattacharyya, S.B. (2016). Introduction to SNOMED CT, Springer.","DOI":"10.1007\/978-981-287-895-3"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e20492","DOI":"10.2196\/20492","article-title":"Assessing the Performance of Clinical Natural Language Processing Systems: Development of an Evaluation Methodology","volume":"9","author":"Canales","year":"2021","journal-title":"JMIR Med. Inform."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3324\/haematol.2013.101378","article-title":"The clinical significance of patients\u2019 sex in chronic lymphocytic leukemia","volume":"99","author":"Catovsky","year":"2014","journal-title":"Haematologica"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1080\/10428190600555819","article-title":"Sex differences in incidence and outcome of chronic lymphocytic leukemia patients","volume":"47","author":"Molica","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cncr.31738","article-title":"Real-world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysis","volume":"125","author":"Seymour","year":"2019","journal-title":"Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e462","DOI":"10.3324\/haematol.2017.185868","article-title":"Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/bjh.14332","article-title":"Real-world clinical experience in the Connect\u00ae chronic lymphocytic leukaemia registry: A prospective cohort study of 1494 patients across 199 US centres","volume":"175","author":"Mato","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_48","unstructured":"E.M.A (2022, July 15). EPAR Imbruvica. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imbruvica."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"26094","DOI":"10.1038\/srep26094","article-title":"Deep Patient: An Unsupervised Representation to Predict the Future of Patients from the Electronic Health Records","volume":"6","author":"Miotto","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Zeiberg, D., Prahlad, T., Nallamothu, B.K., Iwashyna, T.J., Wiens, J., and Sjoding, M.W. (2019). Machine learning for patient risk stratification for acute respiratory distress syndrome. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0214465"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ttbdis.2018.10.010","article-title":"Epidemiology of Lyme disease in Pennsylvania 2006-2014 using electronic health records","volume":"10","author":"Moon","year":"2019","journal-title":"Ticks Tick-Borne Dis."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/16\/4047\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:30:36Z","timestamp":1760128236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/16\/4047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":51,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["cancers15164047"],"URL":"https:\/\/doi.org\/10.3390\/cancers15164047","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]}}}